SCHEMBL3974690

SCHEMBL3974690

O=C([C@@H]1C[C@@H](NCc2ccc(F)cc2F)CN1Cc1ccccc1)N1CCN(c2ccccc2F)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.54
ACHE P22303 2/20 0.54
BACE1 P56817 2/20 0.54
SIGMAR1 Q99720 1/20 0.46
CHRM4 P08173 1/20 0.45
GRM5 P41594 1/20 0.44
KDM4E B2RXH2 8/20 0.43
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 2/20 0.41
ALDH1A1 P00352 4/20 0.41
GAA P10253 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3638100 1.00 BCHE (0.54) BCHEACHEBACE1SIGMAR1CHRM4
SCHEMBL2820374 1.00 BCHE (0.54) BCHEACHEBACE1SIGMAR1CHRM4
SCHEMBL3635928 0.94 BCHE (0.53) BCHEACHEBACE1SIGMAR1GRM5
SCHEMBL2817812 0.94 BCHE (0.53) BCHEACHEBACE1SIGMAR1GRM5
SCHEMBL2819952 0.92 BCHE (0.51) BCHEACHEBACE1SIGMAR1KDM4E
SCHEMBL3632968 0.92 BCHE (0.51) BCHEACHEBACE1SIGMAR1KDM4E
SCHEMBL3975652 0.92 BCHE (0.51) BCHEACHEBACE1SIGMAR1KDM4E
SCHEMBL2817643 0.91 BCHE (0.56) BCHEACHEBACE1SIGMAR1CHRM4
SCHEMBL3637560 0.91 BCHE (0.56) BCHEACHEBACE1SIGMAR1CHRM4
SCHEMBL2817174 0.91 BCHE (0.50) BCHEACHEBACE1SIGMAR1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 BCHE 2225/4885ACHE 548/4885BACE1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.